A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Items 401–500 of 999
Shen, P., Wang, Y., Jia, X., Xu, P., Qin, L., Feng, X., Li, Z., & Qiu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114551 · Cited by 45
Pazos, Y., Alvarez, C. J. P., Camiña, J. P., & Casanueva, F. F. (2007) · Growth Factors · doi:10.1080/08977190801889313 · Cited by 43
Geraghty, P. M., Hardigan, A. A., & Foronjy, R. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0258oc · Cited by 46
“A cigarette smoke–regulated protein in tumor cells, c-Src tyrosine kinase, has increased activity in many human tumor types and correlates with disease stage and patient survival (3).”
BackgroundKobayashi, T., Inoue, T., Shimizu, Y., Terada, N., Maeno, A., Kajita, Y., Yamasaki, T., Kamba, T., Toda, Y., Mikami, Y., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0326 · Cited by 47
Liu, W., Guo, T.-F., Jing, Z.-T., Yang, Z. P., Liu, L., Yang, Y., Lin, X., & Tong, Q.-Y. (2018) · The FASEB Journal · doi:10.1096/fj.201701144r · Cited by 47
“HBc activates Src tyrosine kinase activity by switching inactive pSrc (Tyr527) to active pSrc (Tyr416) Src tyrosine kinase activity is regulated by tyrosine phosphorylation at 2 distinct sites, Tyr416 and Tyr527, with opposite effects (28).”
BackgroundSayed, I. E., Helmy, M. W., & El-Abhar, H. S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.002 · Cited by 47
Fallacara, A. L., Zamperini, C., Podolski-Renić, A., Dinić, J., Stanković, T., Stepanović, M., Mancini, A., Rango, E., Iovenitti, G., Molinari, A., et al. (2019) · Cancers · doi:10.3390/cancers11060848 · Cited by 53
“SFKs are involved in the regulation of cell proliferation, survival, invasion and angiogenesis, thus playing a crucial role in the development and progression of many cancer types, including GBM [18].”
BackgroundLiu, Q., Sheng, Z., Cheng, C., Zheng, H., Lanuti, M. D., Liu, R., Wang, P., Shen, Y., & Xie, Z. (2021) · Advanced Science · doi:10.1002/advs.202102079 · Cited by 49
Jin, A., Zhang, C., Zheng, W., Xian, J., Yang, W., Liu, T., Chen, W., Li, T., Wang, B., Pan, B., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.794 · Cited by 43
Spatiotemporal regulation of Src and its substrates at invadosomes
Boateng, L. R., & Huttenlocher, A. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2012.06.003 · Cited by 53
“Src is a non-receptor tyrosine kinase and its mechanism of activation has been well studied over the past several decades (Martin, 2001; Sicheri et al., 1997; Xu et al., 1997; Yeatman, 2004).”
BackgroundEnhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
Bahman, F., Pittalà, V., Haider, M. A., & Greish, K. F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060559 · Cited by 42
“Src is a protein tyrosine kinase that regulates various cancerous events at an intracellular level, such as cellular adhesion, invasion, growth, survival, and vascular endothelial growth factor (VEGF) expression [14,15].”
BackgroundTanaka, M., Sasaki, K., Kamata, R., Hoshino, Y., Yanagihara, K., & Sakai, R. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01035-08 · Cited by 52
“Src family kinases (SFKs) play important roles in various cell functions such as cell proliferation, cell adhesion, and cell migration (26), and the activities of SFKs often correlate with the malignant potential of cancer and a poor prognosis (37).”
BackgroundSaren, B. N., Mahajan, S., Aalhate, M., Kumar, R., Chatterjee, E., Maji, I., Gupta, U., Guru, S. K., & Singh, P. K. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113631 · Cited by 43
A Golgi-based KDELR-dependent signalling pathway controls extracellular matrix degradation
Ruggiero, C., Fragassi, G., Grossi, M., Picciani, B., Martino, R. D., Capitani, M., Buccione, R., Luini, A., & Sallese, M. (2014) · Oncotarget · doi:10.18632/oncotarget.3270 · Cited by 41
“Src is the best characterized member of the Src family kinases, that includes nine members [17, 18] and regulates a variety of functions, including cell proliferation, differentiation, survival, adhesion, migration and matrix invasion [17].”
BackgroundFeng, Q., Baird, D., Yoo, S., Antonyak, M. A., & Cerione, R. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.098079 · Cited by 52
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer
Edwards, J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003789388 · Cited by 46
“Src consists of four Src-homology (SH) domains: the Nterminal SH4 domain, which contains a myristoylation site necessary for membrane localization; SH3 and SH2 proteinbinding domains; and the catalytic SH1 domain, which contains an ATP-binding site [50].”
BackgroundArcaroli, J. J., Quackenbush, K. S., Powell, R. W., Pitts, T. M., Spreafico, A., Varella‐Garcia, M., Bemis, L., Tan, A. C., Reinemann, J. M., Touban, B. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3167 · Cited by 45
“Activation of Src requires the dephosphorylation of the tyrosine residue at position 527 and subsequent phosphorylation of tyrosine 416, resulting in its catalytic activation (13).”
BackgroundCampbell, E., McDuff, E., Tatarov, O., Tovey, S., Brunton, V., Cooke, T., & Edwards, J. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604768 · Cited by 50
“The precise mechanism of its action has not been fully elucidated, but c-Src is known to interact with a diverse array of molecules, including growth factor receptors and cell –cell adhesion receptors, integrins and steroid receptors including the ER (Ishizawar and Parsons, 2004; Shupnik, 2004) promoting tumour cell p…”
Src Activation Plays an Important Key Role in Lymphomagenesis Induced by FGFR1 Fusion Kinases
Ren, M., Qin, H., Ren, R., Tidwell, J. A., & Cowell, J. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1109 · Cited by 44
“Src overexpression and activation is found in a large number of human malignancies, including lung, breast, pancreatic, colon, and prostate (see review (31-32)).”
Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis
Görtzen, J., Schierwagen, R., Bierwolf, J., Klein, S., Uschner, F. E., van der Ven, P. F., Fürst, D. O., Strassburg, C. P., Laleman, W., Pollok, J.-M., et al. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00359 · Cited by 42
“…at tyrosine 530 on SH2 leads to inactivation of SRC. Dephosphorylation at tyrosine 530 by different kinases, such as SH2-containing phosphatases, allows autophosphorylation at tyrosine 418/419 on SH1, which includes the kinase domain, and leads to activation of SRC (reviewed in Yeatman, 2004).”
BackgroundMethodInfluentialAggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells
Zeng, J., Zhang, H.-Y., Tan, Y.-G., Sun, C., Liang, Y., Yu, J.-Y., & Zou, H.-W. (2018) · BMC Cancer · doi:10.1186/s12885-018-4501-8 · Cited by 33
“c-Src is overexpressed or highly activated in a number of human malignancies, including carcinomas of the breast, lung, colon, esophagus, skin, parotid, cervix, and gastric tissues, as well as in the development of cancer and progression to distant metastases [23].”
Src Family Kinase Inhibitors Block Translation of Alphavirus Subgenomic mRNAs
Broeckel, R. M., Sarkar, S., May, N. A., Totonchy, J. E., Kreklywich, C. N., Smith, P. P., Graves, L. M., DeFilippis, V. R., Heise, M. T., Morrison, T. E., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02325-18 · Cited by 42
New Insights into the Regulation of Ion Channels by Integrins
Becchetti, A., Pillozzi, S., Morini, R., Nesti, E., & Arcangeli, A. (2010) · International review of cytology · doi:10.1016/s1937-6448(10)79005-5 · Cited by 47
Barouch‐Bentov, R., Che, J., Lee, C. C., Yang, Y., Herman, A. E., Jia, Y., Velentza, A. V., Watson, J., Sternberg, L., Kim, S., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.024 · Cited by 42
“SFK hyperactivity is observed in many cancers (Lowell, 2004; Yeatman, 2004).”
Stautz, D., Sanjay, A., Hansen, M. T., Albrechtsen, R., Wewer, U. M., & Kveiborg, M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.017 · Cited by 41
Indovina, P., Giorgi, F. D., Rizzo, V., Khadang, B., Schenone, S., Marzo, D. D., Forte, I. M., Tomei, V., Mattioli, E., D’Urso, V., et al. (2011) · Oncogene · doi:10.1038/onc.2011.286 · Cited by 45
“E-mail: francesca.pentimalli@gmail.com Oncogene (2012) 31, 929–938 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc an important molecular target in cancer therapy (Yeatman, 2004).”
Smith, H. S., & Barkin, R. L. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182456dff · Cited by 44
Qian, X.-L., Zhang, J., Li, P.-Z., Lang, R. G., Li, W., Sun, H., Liu, F.-F., Guo, X.-J., Gu, F., & Fu, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171169 · Cited by 42
Plant Lectins as Medical Tools against Digestive System Cancers
Estrada-Martínez, L. E., Moreno‐Celis, U., Cervantes-Jiménez, R., Ferriz‐Martínez, R. A., Blanco‐Labra, A., & García-Gasca, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071403 · Cited by 41
“Colon cancer metastasis is also related to signalling pathways such as MAPK [146], ribosomal s6 kinase (RSK) via the extracellular signal-regulated kinase (ERK) [147], proto-oncogene tyrosine-protein kinase (Src) [148], and protein kinase B (Akt) [149,150].”
BackgroundWang, Q., More, S. K., Vomhof‐DeKrey, E. E., Golovko, M. Y., & Basson, M. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-51183-z · Cited by 41
Djeungoue‐Petga, M., Lurette, O., Jean, S., Hamel-Côté, G., Martín-Jiménez, R., Bou, M., Cannich, A., Roy, P., & Hébert-Chatelain, É. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2134-8 · Cited by 48
Kim, L. C., Rix, U., & Haura, E. B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003592097 · Cited by 41
“Src family kinases (SFKs) represent a nine-member group of non-receptor tyrosine kinases [1].”
BackgroundDasatinib in recurrent glioblastoma: failure as a teacher
Schiff, D., & Sarkaria, J. N. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov086 · Cited by 44
“Src family members are non-receptor tyrosine kinases that function at the interface between extracellular signals and intracellular signaling pathways.(2,5) Src is normally held in an inactive conformation through intramolecular interaction of the Src homology-2 (SH2) domain with phospho-Y527.”
BackgroundXiao, X., Mruk, D. D., Cheng, F. L., & Cheng, C. Y. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4711-5_15 · Cited by 45
Chen, J., Lan, T., Zhang, W., Dong, L., Kang, N., Fu, M., Liu, B., Liu, K., Zhang, C., Hou, J., et al. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.11.008 · Cited by 40
The SH3 Domain Acts as a Scaffold for the N-Terminal Intrinsically Disordered Regions of c-Src
Maffei, M., Arbesú, M., Roux, A. L., Amata, I., Roche, S., & Pons, M. (2015) · Structure · doi:10.1016/j.str.2015.03.009 · Cited by 40
Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Liu, T., Hu, W., Dalton, H. J., Choi, H. J., Huang, J., Kang, Y., Pradeep, S., Miyake, T. M., Song, J. H., Wen, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1305 · Cited by 42
“Increased Src activity has been demonstrated in colorectal, pancreatic, lung, breast, ovarian, andprostate carcinomas, highlighting Src as a potential therapeutic target (10, 11).”
Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease
Parker, M. I., Nikonova, A. S., Sun, D., & Golemis, E. A. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109497 · Cited by 46
Shrivastav, A., Singh, N. K., Tripathi, P., George, T., Dimmock, J. R., & Sharma, R. K. (2006) · Biochimie · doi:10.1016/j.biochi.2006.03.004 · Cited by 40
Epidermal growth factor receptor family and its role in cancer progression
Nair, P. (2005) · Cited by 51
Paladino, D., Yue, P., Furuya, H., Acoba, J. D., Rosser, C. J., & Turkson, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6635 · Cited by 38
“In addition to Src overexpression and hyperactivation in PDAC [5], our studies and others show active Src in the nuclear compartment of cancer cell lines and patient tumors [10–13], comparable to the other tyrosine kinases reported to be functionally active in the nucleus [14, 33– 35].”
Gao, F., Sabbineni, H., Artham, S., & Somanath, P. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25791 · Cited by 39
“…are of prime importance in regulating endothelial cell survival, proliferation, migration, endothelial-barrier function, and gene expression (Coffer, Jin, & Woodgett, 1998; Eliceiri et al., 1999; Laird et al., 2003; Minshall, Tiruppathi, Vogel, & Malik, 2002; Shiojima & Walsh, 2002; Yeatman, 2004).”
Alternative Splicing Modulates Autoinhibition and SH3 Accessibility in the Src Kinase Fyn
Brignatz, C., Paronetto, M. P., Opi, S., Cappellari, M., Audebert, S., Feuillet, V., Bismuth, G., Roche, S., Arold, S. T., Sette, C., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00398-09 · Cited by 39
Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., & Hochhaus, A. (2008) · Haematologica · doi:10.3324/haematol.12793 · Cited by 38
“Patients on dasatinib therapy (CML, n=17; GIST, n=1) 18 Age at start of dasatinib, years 57 (26-75) % male 50 Previous therapy 18 (100) Imatinib 4 (22) Imatinib, HU 1 (6) Imatinib, IFN 4 (22) Imatinib, HU, IFN 6 (33) Imatinib, HU, IFN, AraC 2 (11) Follow-up of all patients after diagnosis, months 75 (10-198) Follow-up…”
BackgroundSrc-dependent signalling pathway regulation by sex-steroid hormones: Therapeutic implications
Migliaccio, A., Castoria, G., & Auricchio, F. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.12.009 · Cited by 39
“Inhibitors of Src and different forms of PI3K are actively investigated as potential therapeutic agents of mammary cancer (Knight & Shokat, 2005; Yeatman, 2004).”
BackgroundInfluentialAhn, J., & Lee, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.034 · Cited by 38
“Elevated expression and activation of Srcfamily tyrosine kinase have been implicated in a variety of cancers, including glioblastoma, colon, lung, breast, and prostate cancers [12].”
BackgroundTranslational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase
Liang, F., Luo, Y., Dong, Y., Walls, C. D., Liang, J., Jiang, H.-Y., Sanford, J. R., Wek, R. C., & Zhang, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708285200 · Cited by 40
Spreafico, A., Chi, K. N., Sridhar, S. S., Smith, D. C., Carducci, M. A., Kavsak, P. A., Wong, T., Wang, L. E., Ivy, S. P., Mukherjee, S. D., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0106-5 · Cited by 41
“Furthermore, previous data have shown a proangiogenic role of Src through hypoxia-driven VEGF induction [16, 25].”
BackgroundDrosophila actin-Capping Protein limits JNK activation by the Src proto-oncogene
Fernández, B. G., Jezowska, B., & Janody, F. (2013) · Oncogene · doi:10.1038/onc.2013.155 · Cited by 38
Migfilin Interacts with Src and Contributes to Cell-Matrix Adhesion-mediated Survival Signaling
Zhao, J., Zhang, Y., Ithychanda, S. S., Tu, Y., Chen, K., Qin, J., & Wu, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045021 · Cited by 37
Shen, K., Moroco, J. A., Patel, R. K., Shi, H., Engen, J. R., Dorman, H. R., & Smithgall, T. E. (2018) · Science Signaling · doi:10.1126/scisignal.aat5916 · Cited by 37
Choi, Y. D., Jung, J., Baek, M., Khan, S., Song, P. I., Ryu, S., Koo, J.-Y., Chauhan, S. C., Tsin, A. T. C., Choi, C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103586 · Cited by 37
Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCδ
Yamaguchi, K., Richardson, M. D., Bigner, D. D., & Kwatra, M. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1030-3 · Cited by 38
“Based on these observations, there currently is renewed interest in the evaluation of Src inhibitors as anti-cancer agents [28, 29].”
Anbalagan, M., Moroz, K., Ali, A. M., Carrier, L., Glodowski, S., & Rowan, B. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033017 · Cited by 39
“Src remains inactive in the cytoplasm when it is phosphorylated at Y530; once dephosphorylated, Src translocates to the cell membrane and becomes fully activated by autophosphorylation at Y416 [14,15,16,17].”
BackgroundMolecular Dissection of AKT Activation in Lung Cancer Cell Lines
Guo, Y., Du, J., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0558 · Cited by 41
“SRC tyrosine family kinases are key regulators of cellular proliferation, survival, motility, and invasiveness (30).”
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Lue, H.-W., Cole, B. C., Rao, S. A. M., Podolak, J., Gaest, A. V., King, C. J., Eide, C. A., Wilmot, B., Xue, C., Spellman, P. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5971 · Cited by 37
Differential subcellular membrane recruitment of Src may specify its downstream signalling
de Diesbach, P., Medts, T., Carpentier, S., D’Auria, L., Smissen, P. V. D., Platek, A., Mettlen, M., Caplanusi, A., van den Hove, M.-F., Tyteca, D., et al. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.01.015 · Cited by 37
Kratimenos, P., Koutroulis, I., Marconi, D., Syriopoulou, V., Delivoria‐Papadopoulos, M., Chrousos, G. P., & Theocharis, S. E. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.952280 · Cited by 50
“c-Src has been shown to promote tumorigenicity [42,43].”
Sato, H., Nagashima, K., Ogura, M., Sato, Y., Tahara, Y., Ogura, K., Yamano, G., Sugizaki, K., Fujita, N., Tatsuoka, H., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12407 · Cited by 40
Asbagh, L. A., Vázquez, I., Vecchione, L., Budínská, E., de Vriendt, V., Baietti, M. F., Steklov, M. Y., Jacobs, B., Hoe, N., Singh, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2458 · Cited by 36
“Importantly, prior studies have reported that elevated SRC activity in CRC is associated with advanced malignancies and metastatic spread [24, 41–44].”
van Erp, A. E. M., Hillebrandt-Roeffen, M. H. S., van Houdt, L., Fleuren, E. D. G., van der Graaf, W. T. A., & Versleijen‐Jonkers, Y. M. H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0528-z · Cited by 36
“tyrosine kinases, the exact role of Src in oncogenesis is still not clear [41].”
BackgroundScott, A. J., Song, E., Bagby, S. M., Purkey, A., McCarter, M. D., Gajdos, C., Quackenbush, K. S., Cross, B. R., Pitts, T. M., Tan, A. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187173 · Cited by 40
Src mediates TGF‐β‐induced intraocular pressure elevation in glaucoma
Tsukamoto, T., Kajiwara, K., Nada, S., & Okada, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27044 · Cited by 36
“Dysregulation of SFKs is associated with various diseases, including cancer and fibrosis (Massip Copiz & Santa Coloma, 2016; Wang & Zhuang, 2017; Yeatman, 2004).”
BackgroundMohammed, S., Shamseddine, A. A., Newcomb, B., Chavez, R. S., Panzner, T. D., Lee, A. H., Canals, D., Okeoma, C. M., Clarke, C. J., & Hannun, Y. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01452-5 · Cited by 38
“Of these, Src, Fyn, and Yes are expressed in a wide range of tissues [33] and have been shown to promote cell migration/invasion [35, 40, 55].”
BackgroundElshazly, A. M., & Gewirtz, D. A. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.09 · Cited by 40
Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase
Batuello, C. N., Hauck, P. M., Gendron, J. M., Lehman, J. A., & Mayo, L. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416656112 · Cited by 38
“Specifically, c-Src is involved in a multitude of tumor progression properties including survival, angiogenesis, migration, and adhesion (1).”
BackgroundSrc tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen, T., George, J. A., & Taylor, C. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00002 · Cited by 42
Zou, H., Luo, J., Guo, Y., Tong, T., Liu, Y., Chen, Y., Xiao, Y., Ye, L., Zhu, C., Deng, L., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04688-w · Cited by 40
“Furthermore, SRC activation has been discovered to involve multiple processes underlying tumor development and progression, including cell proliferation, migration, invasion, and metastasis [10, 18].”
BackgroundStrategies to Explore New Approaches in the Investigation and Treatment of Osteosarcoma
Kim, S. Y., & Helman, L. J. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_31 · Cited by 41
Radiation promotes malignant phenotypes through SRC in breast cancer cells
Kim, R., Cui, Y., Yoo, K.-C., Kim, I., Lee, M., Choi, Y. H., Suh, Y., & Lee, S. (2014) · Cancer Science · doi:10.1111/cas.12574 · Cited by 35
Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Filosto, S., Baston, D. S., Chung, S., Becker, C. R., & Goldkorn, T. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1029 · Cited by 39
“Initially, we found that Src, a proto-oncogene and tyrosine kinase often over-expressed in cancer (35-39), was robustly activated and bound to both the WT and L858R MT EGFR during CS exposure (Fig.”
BackgroundVignaroli, G., Iovenitti, G., Zamperini, C., Coniglio, F., Calandro, P., Molinari, A., Fallacara, A. L., Sartucci, A., Calgani, A., Colecchia, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00637 · Cited by 35
Requirement of N-Myristoyltransferase 1 in the Development of Monocytic Lineage
Shrivastav, A., Varma, S., Lawman, Z., Yang, S. H., Ritchie, S. A., Bonham, K., Singh, S. M., Saxena, A., & Sharma, R. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1019 · Cited by 36
“Overexpression and/or activation of c-Src is linked genetically and biochemically to the development of several human cancers, especially those of the colon and breast (9, 10).”
BackgroundOrgan, S. L., Tong, J., Taylor, P. P., St‐Germain, J. R., Navab, R., Moran, M. F., & Tsao, M. (2011) · Journal of Proteome Research · doi:10.1021/pr200238t · Cited by 36
HNF4α: A New Biomarker in Colon Cancer?
Chellappa, K., Robertson, G. R., & Sladek, F. M. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.23 · Cited by 35
“We identified the probable mechanism for the differential loss of nuclear P1-HNF4α by showing that Src tyrosine kinase, a known player in CRC [14], phosphorylates Tyr14 in the HNF4α A/B domain.”
BackgroundA novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model
Serrels, B., Serrels, A., Mason, S. M., Baldeschi, C., Ashton, G. H. S., Canel, M., Mackintosh, L. J., Doyle, B. J., Green, T. P., Frame, M. C., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn278 · Cited by 39
N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src
Krasnowska, E. K., Pittaluga, E., Brunati, A. M., Brunelli, R., Costa, G., Spirito, M. D., Serafino, A., Ursini, F., & Parasassi, T. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.012 · Cited by 37
“Moreover, to perform its pleiotropic functions, c-Src has to be bound to cellular partners, including the cell membrane, cell-cell and cell-substratum adhesion complex, and cytoskeletal elements, whereas inactive c-Src is reported to be stored in perinuclear compartments [7,11].”
BackgroundInfluentialThe pK a of Brønsted acids controls their reactivity with diazo compounds
Fei, N., Sauter, B., & Gillingham, D. G. (2016) · Chemical Communications · doi:10.1039/c6cc03561b · Cited by 35
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma
Hu, X. F., Yang, E., Li, J., & Xing, P. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1261 · Cited by 35
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
Peikert, K., Federti, E., Mattè, A., Constantin, G., Pietronigro, E. C., Fabene, P. F., Defilippi, P., Turco, E., Gallo, F. D., Pucci, P., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01181-y · Cited by 36
“However, the accumulation of active Src family kinases might be per se cytotoxic, contributing to impaired autophagy as reported in cancer cells [72, 73] The accumulation of At8- and At180-phosphorylated tau proteins and γ-synuclein as well as of polyubiquinated proteins in Vps13a−/− mouse basal ganglia is consistent…”
BackgroundBiosensors based on peptide exposure show single molecule conformations in live cells
Liu, B., Stone, O. J., Pablo, M., Herron, J. C., Nogueira, A. T., Dağliyan, O., Grimm, J. B., Lavis, L. D., Elston, T. C., & Hahn, K. M. (2021) · Cell · doi:10.1016/j.cell.2021.09.026 · Cited by 36
“Our studies focus on Src at integrin-based adhesion complexes, where Src is at the intersection of several signaling pathways (Brown andCooper, 1996; Huveneers and Danen, 2009; Parsons and Parsons, 2004; Sato et al., 2009; Thomas and Brugge, 1997; Yeatman, 2004).”
BackgroundNongenomic Activity of Ligands in the Association of Androgen Receptor with Src
Kim, S. B., Kanno, A., Ozawa, T., Tao, H., & Umezawa, Y. (2007) · ACS Chemical Biology · doi:10.1021/cb7000439 · Cited by 43
Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy
Nagathihalli, N. S., Singh, O. V., & Merchant, N. B. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.70 · Cited by 35
Weiss, A., Baumgartner, M., Radziwill, G., Dennler, J., & Moelling, K. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.09.062 · Cited by 34
Src, p130Cas, and Mechanotransduction in Cancer Cells
Matsui, H., Harada, I., & Sawada, Y. (2012) · Genes & Cancer · doi:10.1177/1947601912461443 · Cited by 36
“Other SFKs include Yes, Fyn, Lyn, Blk, Fgr, Lck, Hck, and Yrk.(25) A Src molecule contains 3 conserved Src homology (SH) domains: SH1, SH2, and SH3 (Fig.”
BackgroundIntegrins Uncouple Src-induced Morphological and Oncogenic Transformation
Huveneers, S., Arslan, S., van de Water, B., Sonnenberg, A., & Danen, E. H. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800927200 · Cited by 34
Sirvent, A., Vigy, O., Orsetti, B., Urbach, S., & Roche, S. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018168 · Cited by 33
“It also has oncogenic activity when deregulated, a role originally described for the constitutively active v-SRC (2) that has since been observed in a large variety of human cancers (3).”
BackgroundYagi, R., Tanaka, M., Sasaki, K., Kamata, R., Nakanishi, Y., Kanai, Y., & Sakai, R. (2010) · Oncogene · doi:10.1038/onc.2010.522 · Cited by 33
“Src pathways are implicated in cancer progression because SFK activity and expression and tyrosine phosphorylation of Src substrates are often elevated in advanced stages of cancer (Yeatman, 2004).”
BackgroundBrought to life: targeted activation of enzyme function with small molecules
Bishop, A. C., & Chen, V. L. (2008) · Journal of Chemical Biology · doi:10.1007/s12154-008-0012-4 · Cited by 35
“Cole and co-workers then expressed R338A/Y527F c-Src (the second mutation was designed to prevent down-regulation of Src function by Csk phosphorylation [31]) in a SYF (Src, Yes, and Fyn deleted) mouse embryonic fibroblast cell line [30].”
BackgroundLi, H., Huang, F., Fan, L., Jiang, Y., Wang, X., Li, J., Wang, Q., Pan, H., Sun, J., Cao, X., et al. (2013) · Oncogene · doi:10.1038/onc.2013.408 · Cited by 33
HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women
Batschauer, A. P. D. B., Cruz, N., Souza, V. C. D. O., Coelho, F. F., Santos, I. R., Alves, M. T., Fernandes, A. P., Ferriani, M. D. G. C., & Gomes, K. B. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0895-1 · Cited by 33
“However, genetic screening in all women is difficult, restricting to only those with high-risk family history [3].”
BackgroundZhang, J., Yang, H. J., Huang, T., Yang, S., & Chen, L. (2016) · Neurocomputing · doi:10.1016/j.neucom.2015.09.136 · Cited by 33
Yang, L., Hu, Z., Zhu, J., Liang, Q., Zhou, H., Li, J., Fan, X., Zhao, Z., Pan, H., & Fei, B. (2020) · BioMed Research International · doi:10.1155/2020/3860213 · Cited by 33
“Src, a serine/threonine kinase, is important in the development of many solid tumors [63].”
BackgroundDasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
Xiao, J., Xu, M., Hou, T., Huang, Y., Yang, C., & LI, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3784 · Cited by 36
“SFKs consist of nine non-receptor tyrosine kinases that share a similar structure (4).”
Naringin suppresses the metabolism of A375 cells by inhibiting the phosphorylation of c-Src
Guo, B., Zhang, Y., Hui, Q., Wang, H., & Tao, K. X. (2015) · Tumor Biology · doi:10.1007/s13277-015-4235-z · Cited by 33
Regulation of c‐Src by binding to the PDZ domain of AF‐6
Radziwill, G., Weiss, A., Heinrich, J., Baumgartner, M., Boisguérin, P., Owada, K. M., & Moelling, K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601706 · Cited by 34
Ion channels and transporters as therapeutic targets in the pulmonary circulation
Olschewski, A., Papp, R., Nagaraj, C., & Olschewski, H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.001 · Cited by 40
Han, S., Meng, Y., Tong, Q., Li, G., Zhang, X., Chen, Y., Hu, S., Zheng, L., Tan, W., Li, H., et al. (2013) · mAbs · doi:10.4161/mabs.27443 · Cited by 32
“The nonreceptor tyrosine kinase c-SRC (SRC) is overexpressed in a wide range of tumors.(7) The aberrant activation of SRC regulates multiple functions during tumor progression, such as apoptosis, proliferation, cell adhesion, cell migration and invasion, angiogenesis, and metastasis.”
BackgroundYamamoto, T., Mori, T., Sawada, M., Matsushima, H., Ito, F., Akiyama, M., & Kitawaki, J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1286-x · Cited by 31
“A Src signaling is important in multiple physiological homeostatic pathways that regulate cell proliferation, cell survival, cytoskeleton regulation, intracellular contacts, cell-matrix adhesion, motility, and migration [25,26].”
BackgroundZheng, L.-Z., Cao, H.-J., Chen, S.-H., Tang, T., Fu, W.-M., Huang, L., Chow, D. H. K., Wáng, Y. X. J., Griffith, J. F., He, W., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2542 · Cited by 34
“Src (encodedby the c-srcgene) is involved in regulatinga range of cellular processes, including vascular proliferation, adhesion, motility, and survival.((24,25)) As a downstream molecule of VEGF signaling, Src participates in mediating VEGF-induced vascular permeability but not in VEGF-mediated angiogenesis.”
Background
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.